Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

557
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
557
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

527
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
527
Angina IV: Management01:26

Angina IV: Management

425
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
425
Angina II: Classification01:27

Angina II: Classification

603
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
603
Angina V: Nursing Management01:20

Angina V: Nursing Management

520
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
520

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutation-driven mechanisms underlying antibiotic resistance of Helicobacter pylori in Asia: A systematic review and meta-analysis (2000-2024).

Microbial pathogenesis·2026
Same author

An Unusual Case of Juvenile Dermatomyositis Complicated by Macrophage Activation Syndrome.

International journal of dermatology·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Neuroprotective Potential of Free Radical-Scavenging Nanoparticles in Addressing Inflammation and Obesity.

IET nanobiotechnology·2025
Same author

Results of a 2025 UK and Ireland survey on the use of minimal phototoxic dose testing before psoralen with ultraviolet A radiation phototherapy.

Clinical and experimental dermatology·2025

Related Experiment Video

Updated: Apr 3, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.9K

Topical Nitroglycerine in Perniosis/Chilblains.

Prashant Verma

    Skinmed
    |September 19, 2015
    PubMed
    Summary

    Topical nitroglycerine ointment effectively treats perniosis, with most patients showing lesion regression within two weeks. This vasodilator offers a promising new option for managing this condition.

    Area of Science:

    • Dermatology
    • Pharmacology

    Background:

    • Perniosis treatment options are currently limited and often inadequate.
    • Severe perniosis can cause significant discomfort and requires effective therapeutic interventions.

    Purpose of the Study:

    • To evaluate the efficacy and therapeutic response of topical 0.2% nitroglycerine ointment in patients with severe perniosis.

    Main Methods:

    • Twenty-two patients with clinically diagnosed severe perniosis received topical 0.2% nitroglycerine.
    • Therapeutic response was assessed using digital photography and patient self-report on a 3-point scale for clinical appearance, irritation, pain, and soreness.

    Main Results:

    • 18 out of 22 patients experienced lesion regression within one week, with complete regression in two weeks.

    More Related Videos

    Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
    06:39

    Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

    Published on: August 18, 2016

    17.1K
    Author Spotlight: Advancing Varicocele Treatment with Neuromuscular Electrical Stimulation
    03:19

    Author Spotlight: Advancing Varicocele Treatment with Neuromuscular Electrical Stimulation

    Published on: August 30, 2024

    1.4K

    Related Experiment Videos

    Last Updated: Apr 3, 2026

    Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
    07:59

    Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

    Published on: April 4, 2022

    1.9K
    Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
    06:39

    Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

    Published on: August 18, 2016

    17.1K
    Author Spotlight: Advancing Varicocele Treatment with Neuromuscular Electrical Stimulation
    03:19

    Author Spotlight: Advancing Varicocele Treatment with Neuromuscular Electrical Stimulation

    Published on: August 30, 2024

    1.4K
  • Two patients with delayed response and two with relapses also showed successful outcomes with continued or repeated treatment.
  • Response time correlated with disease duration, with longer-standing cases showing delayed improvement.

    • Conclusions:

    • Topical 0.2% nitroglycerine ointment demonstrates significant efficacy in treating severe perniosis.
    • This vasodilator presents a promising alternative treatment for perniosis, particularly for severe cases.
    • Further investigation may be warranted to optimize treatment protocols based on disease duration.